US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Enlivex Therapeutics Ltd.

0.9845

+0.02452.55%

Volume:26.23K

Turnover:25.19K

Market Cap:23.28M

PE:-1.35

High:1.00

Open:0.9700

Low:0.9300

Close:0.9600

Loading ...

Overview Company News Filings

Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

Enlivex Therapeutics Is Maintained at Buy by D. Boral Capital

Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Analysts Offer Insights on Healthcare Companies: Harvard Bioscience (HBIO) and Enlivex (ENLV)

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Enlivex Therapeutics Is Maintained at Buy by D. Boral Capital

Enlivex announces interim 6-month efficacy data from Phase I of Allocetra trial

Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics (NASDAQ:ENLV) Hails Positive Trial Results for Allocetra Treatment of Knee Osteoarthritis

Enlivex Issues Urgent Statement on Fraudulent News Dissemination

Enlivex Therapeutics Gets Approval for Phase 1 Trial of Allocetra to Treat Osteoarthritis

MT Newswires Live

Enlivex Therapeutics Is Maintained at Buy by D. Boral Capital

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Trump's crypto advocacy steers businesses away from traditional treasury assets

Enlivex Reports Positive Results in Osteoarthritis Trial

Enlivex announces interim efficacy data from Phase I Allocetra trial

Enlivex Therapeutics Faces Financial Challenges Amid Losses

Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ENLV/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ENLV","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ENLV\",,,,,undefined,":{"symbol":"ENLV","market":"US","secType":"STK","nameCN":"Enlivex Therapeutics Ltd.","latestPrice":0.9845,"timestamp":1745611200000,"preClose":0.96,"halted":0,"volume":26226,"delay":0,"floatShares":17725396,"shares":23650989,"eps":-0.73189,"marketStatus":"Pre-Mkt","change":0.0245,"latestTime":"04-28 06:44:57 EDT","open":0.97,"high":1,"low":0.93,"amount":25194.2717826,"amplitude":0.072917,"askPrice":1.02,"askSize":1291,"bidPrice":0.9604,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":-0.73189,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745847000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1406779200000,"exchange":"NASDAQ","adjPreClose":0.97,"postHourTrading":{"tag":"盘后","latestPrice":0.99,"preClose":0.9845,"latestTime":"19:52 EDT","volume":251,"amount":248.48,"timestamp":1745625161754},"volumeRatio":0.5318605275566856,"impliedVol":0.827,"impliedVolPercentile":0.8153},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ENLV\",,,,,undefined,":{"symbol":"ENLV","floatShares":17725396,"roa":"-30.10%","roe":"-55.95%","lyrEps":-0.73189,"volumeRatio":0.5318605275566856,"shares":23650989,"dividePrice":0,"high":1,"amplitude":0.072917,"preClose":0.96,"low":0.93,"week52Low":0.8101,"pbRate":"0.99","week52High":1.84,"institutionHeld":0,"latestPrice":0.9845,"committee":0.074884,"eps":-0.73189,"divideRate":0,"volume":26226,"delay":0,"ttmEps":-0.73189,"open":0.97,"prevYearClose":1.17,"prevWeekClose":0.9845,"prevMonthClose":0.9702,"prevQuarterClose":0.9702,"fiveDayClose":0.86,"twentyDayClose":1.01,"sixtyDayClose":1.109},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ENLV\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529631683","title":"Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2529631683","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529631683?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:30","pubTimestamp":1745411400,"startTime":"0","endTime":"0","summary":"Presentations to underscore AllocetraTM’s novel mechanism targeting immune imbalance in joint disease. Ness-Ziona, Israel, April 23, 2025  -- Enlivex Therapeutics Ltd. , a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present two poster abstracts at the Osteoarthritis Research Society International  2025 World Congress on Osteoarthritis, taking place April 24-27, 2025, in Incheon , South Korea.“These presentations at OARSI 2025 will highlight the growing body of evidence supporting Allocetra’sTM potential as a novel therapeutic approach for osteoarthritis,” said Oren Hershkovitz, PhD, Chief Executive Officer of Enlivex. “We believe that restoring macrophage homeostasis may address the underlying drivers of chronic joint inflammation and cartilage degradation, potentially offering a promising new treatment pathway for millions of patients worldwide.”The presentations will feature data from both preclinical and clinical studies evaluating All","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enlivex-therapeutics-showcase-allocetra-potential-123000648.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4007","BK4139","ENLV"],"gpt_icon":0},{"id":"2529576806","title":"Enlivex Announces Completion of Enrollment In The Phase II stage Of  Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2529576806","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529576806?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:30","pubTimestamp":1745238600,"startTime":"0","endTime":"0","summary":"Nes-Ziona, Israel, April 21, 2025  -- Enlivex Therapeutics Ltd. , a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company completed enrollment of all patients in the Phase II stage of its randomized, controlled, blinded Phase I/II trial of Allocetra in patients with moderate to severe knee osteoarthritis. Overall, 133 patients were randomized and treated in the Phase II stage.Oren Hershkovitz, Ph.D, CEO of Enlivex, commented, “We are pleased to have completed the recruitment of patients in the Phase II stage of this trial, which follows the recently announced promising initial efficacy data from the Phase I stage. We therefore reiterate our timeline objective to obtain 3-month topline data by August 2025. We believe Allocetra has the potential to transform the way osteoarthritis patients are being treated today, and we are eager to receive the topline data of the trial.”Osteoarthritis is by far the most common form of arthritis, affecting more ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enlivex-announces-completion-enrollment-phase-123000491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ENLV"],"gpt_icon":0},{"id":"2524926370","title":"Enlivex Therapeutics Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2524926370","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524926370?lang=en_us&edition=fundamental","pubTime":"2025-04-03 22:03","pubTimestamp":1743688980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ENLV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 03, 2025 10:03 ET (14:03 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ENLV"],"gpt_icon":0},{"id":"2524251158","title":"Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2524251158","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524251158?lang=en_us&edition=fundamental","pubTime":"2025-04-03 20:00","pubTimestamp":1743681600,"startTime":"0","endTime":"0","summary":"Temporomandibular joint  osteoarthritis is a degenerative, debilitating and progressive disease, the second most common musculoskeletal condition affecting five to 12% of the population globally. TMJ causes pain and stiffness in the jaw, making it difficult to chew. TMJ osteoarthritis currently has no long-term effective treatments. Ness-Ziona, Israel, April 03, 2025  -- Enlivex Therapeutics Ltd. , a clinical-stage macrophage reprogramming immunotherapy company, today announced that the first patient has been dosed in an investigator-initiated Phase I trial to evaluate the safety, tolerability and initial efficacy of Allocetra for injection into the temporomandibular joint  in patients suffering from TMJ osteoarthritis.Dr. Einat Galamidi, CMO of Enlivex, commented, “This study will provide a preliminary evaluation of the safety and potential effect of AllocetraTM for the treatment of TMJ osteoarthritis, which affects a joint that is critical for daily function. We are pleased to report","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enlivex-announces-dosing-first-patient-120000506.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ENLV"],"gpt_icon":0},{"id":"2522606203","title":"Analysts Offer Insights on Healthcare Companies: Harvard Bioscience (HBIO) and Enlivex (ENLV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522606203","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522606203?lang=en_us&edition=fundamental","pubTime":"2025-03-25 14:30","pubTimestamp":1742884215,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Harvard Bioscience (HBIO – Research Report) and Enli...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-harvard-bioscience-hbio-and-enlivex-enlv?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-harvard-bioscience-hbio-and-enlivex-enlv?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4139","ENLV","HBIO","HCSG","BK4121"],"gpt_icon":0},{"id":"2520522829","title":"Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2520522829","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520522829?lang=en_us&edition=fundamental","pubTime":"2025-03-17 20:00","pubTimestamp":1742212800,"startTime":"0","endTime":"0","summary":"Nes-Ziona, Israel, March 17, 2025  -- Enlivex Therapeutics Ltd. , a clinical-stage macrophage reprogramming immunotherapy company, today announced that the China National Intellectual Property Administration  issued a notice of allowance for patent application number 2020800620493. Once issued, the resulting patent will provide Enlivex with added intellectual property protection in China through at least 2040 with claims covering methods of using Allocetra to treat subjects with osteoarthritis. The Company expects that this new patent will be issued in China during the first half of 2025.Enlivex recently reported positive interim six  months efficacy data from the first stage of its ongoing randomized, multi-country Phase I/II Allocetra trial in patients with moderate to severe knee osteoarthritis.Statistically significant, 47.0% average reduction of reported pain , compared to average pain level at baseline. 46% improvement in joint function and 40% improvement in joint stiffness. Eff","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enlivex-receives-notice-allowance-chinese-120000844.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ENLV"],"gpt_icon":0},{"id":"2516584486","title":"Enlivex Therapeutics Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2516584486","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516584486?lang=en_us&edition=fundamental","pubTime":"2025-03-03 23:54","pubTimestamp":1741017240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ENLV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 03, 2025 10:54 ET (15:54 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","ENLV"],"gpt_icon":0},{"id":"2516635024","title":"Enlivex announces interim 6-month efficacy data from Phase I of Allocetra trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2516635024","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516635024?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:25","pubTimestamp":1741008339,"startTime":"0","endTime":"0","summary":"Enlivex Therapeutics (ENLV) announced positive interim six-month efficacy data from the Phase I stage of its randomized, multi-country Phase I/II A...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/enlivex-announces-interim-6-month-efficacy-data-from-phase-i-of-allocetra-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/enlivex-announces-interim-6-month-efficacy-data-from-phase-i-of-allocetra-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ENLV"],"gpt_icon":0},{"id":"2516463995","title":"Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2516463995","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516463995?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:22","pubTimestamp":1741008120,"startTime":"0","endTime":"0","summary":"Nes-Ziona, Israel, March 03, 2025  -- Enlivex Therapeutics Ltd. , a clinical-stage macrophage reprogramming immunotherapy company, today announced positive interim six-month efficacy data from the Phase I stage of its randomized, multi-country Phase I/II Allocetra trial in patients with moderate to severe knee osteoarthritis.46% improvement in joint function and 40% improvement in joint stiffness. The Company previously announced positive 3-month interim safety and efficacy results for the first 12 patients treated in the Phase I stage. The previously announced data demonstrated a marked statistically significant improvements in all key efficacy endpoints, including 50%1average pain reduction and 42% and 37% improvement in functionality and stiffness, respectively, compared to the baseline2. All 12 patients in the Phase I stage completed the assessment at 6 months following the last injection3, and the data from such assessments showed a statistically significant 47.0% average reductio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enlivex-announces-positive-interim-data-132200300.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ENLV","BK4139"],"gpt_icon":0},{"id":"2512668951","title":"Enlivex Therapeutics (NASDAQ:ENLV) Hails Positive Trial Results for Allocetra Treatment of Knee Osteoarthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2512668951","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512668951?lang=en_us&edition=fundamental","pubTime":"2025-02-18 22:30","pubTimestamp":1739889004,"startTime":"0","endTime":"0","summary":"Israeli macrophage reprogramming immunotherapy company Enlivex Therapeutics ($ENLV) announced “highly positive” clinical trial results for its nove...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/enlivex-therapeutics-nasdaqenlv-hails-positive-trial-results-for-allocetra-treatment-of-knee-osteoarthritis?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/enlivex-therapeutics-nasdaqenlv-hails-positive-trial-results-for-allocetra-treatment-of-knee-osteoarthritis?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TQQQ","QID","ENLV","IE00B64PRP62.GBP","NVIW.SI","NQmain","PSQ",".IXIC","SQQQ","USAW.SI","BK4585","MNQmain","LU2210150020.SGD","USJW.SI","IE00BKPKM429.USD","LU2210149790.SGD","BK4588","IE00B3QW5Z07.USD","BK4112","LU2095319765.USD","TSYW.SI","NDAQ","QLD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2512615325","title":"Enlivex Issues Urgent Statement on Fraudulent News Dissemination","url":"https://stock-news.laohu8.com/highlight/detail?id=2512615325","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512615325?lang=en_us&edition=fundamental","pubTime":"2025-02-18 19:20","pubTimestamp":1739877600,"startTime":"0","endTime":"0","summary":"Ness-Ziona, Israel, Feb. 18, 2025  -- Enlivex Therapeutics Ltd. , a clinical-stage macrophage reprogramming immunotherapy company, alerts investors and the public that a completely false and misleading report regarding the Company was intentionally published this morning by the website Tipranks.com claiming that the Company has suspended its stock trading due to an internal investigation. These reports are completely unfounded and constitute fake news. The Company continues to operate normally, and its shares continue to trade regularly on the Tel Aviv Stock Exchange and NASDAQ Stock Exchange without any interruption.The Company unequivocally denies the claims made in this false report and urges investors to rely only on official communications from the Company, including press releases, filings with the U.S. Securities and Exchange Commission, and statements from verified Company channels.Investors and stakeholders with concerns or questions are encouraged to contact Shachar Shlosberg","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enlivex-issues-urgent-statement-fraudulent-112000943.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ENLV","BK4139"],"gpt_icon":0},{"id":"2490986415","title":"Enlivex Therapeutics Gets Approval for Phase 1 Trial of Allocetra to Treat Osteoarthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2490986415","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490986415?lang=en_us&edition=fundamental","pubTime":"2024-12-12 00:02","pubTimestamp":1733932933,"startTime":"0","endTime":"0","summary":"Enlivex Therapeutics  said Wednesday it received authorization from the Israeli Ministry of Health to start a phase 1 clinical trial of Allocetra after injection into the temporomandibular joint in osteoarthritis patients.The company intends to evaluate the frequency and severity of adverse events, including serious adverse events, as the primary safety endpoint of the trial, which will enroll six participants, it added.Enlivex said that efficacy endpoints will focus on changes from baseline in temporomandibular joint pain, joint functionality, and other disease parameters for up to 12 months following the injection of Allocetra.Shares of Enlivex Therapeutics were down 1.6% in recent trading.Price: 1.23, Change: -0.02, Percent Change: -1.60","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ENLV","BK4139","LENZ"],"gpt_icon":0},{"id":"2490914863","title":"Enlivex Therapeutics Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2490914863","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490914863?lang=en_us&edition=fundamental","pubTime":"2024-12-11 22:51","pubTimestamp":1733928660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ENLV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 11, 2024 09:51 ET (14:51 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENLV","LENZ"],"gpt_icon":0},{"id":"2490810850","title":"Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2490810850","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490810850?lang=en_us&edition=fundamental","pubTime":"2024-12-11 21:30","pubTimestamp":1733923800,"startTime":"0","endTime":"0","summary":"Ness-Ziona, Israel, Dec. 11, 2024  -- Enlivex Therapeutics Ltd. , a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Israeli Ministry of Health authorized the initiation of an investigator-initiated Phase I trial to evaluate the safety, tolerability and initial efficacy of Allocetra for injection into the temporomandibular joint  in patients suffering from TMJ osteoarthritis.The study will be conducted by the Rheumatology Unit at Sheba Medical Center in collaboration with the Department of Oral and Maxillofacial Surgery. Notably, Sheba Medical Center was recently ranked among the top 10 hospitals in the world by Newsweek.Dr. Oren Hershkovitz, CEO of Enlivex, commented, “TMJ osteoarthritis is a unique disease that can affect young, otherwise healthy individuals, causing substantial pain and impairment in oral function. In many cases, existing therapies fail to provide long-term relief, forcing patients to undergo multiple surgeries as their disease","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FIOoTYlhU1922yeFquiUhQ--~B/aD00Mjt3PTE1MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/500cdd9202d9cca9833167f70a85d1ba","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FIOoTYlhU1922yeFquiUhQ--~B/aD00Mjt3PTE1MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/500cdd9202d9cca9833167f70a85d1ba"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enlivex-receives-regulatory-authorization-initiation-133000186.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ENLV"],"gpt_icon":0},{"id":"2489469155","title":"Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2489469155","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489469155?lang=en_us&edition=fundamental","pubTime":"2024-12-05 23:49","pubTimestamp":1733413740,"startTime":"0","endTime":"0","summary":"Nes-Ziona, Israel, Dec. 05, 2024  -- Enlivex Therapeutics Ltd. , a clinical-stage macrophage reprogramming immunotherapy company, today announced positive interim efficacy data from the Phase I stage of its randomized, multi-country Phase I/II Allocetra trial in patients with moderate to severe knee osteoarthritis.The multi-center Phase I/II clinical trial consists of two stages. The first stage, which was successfully completed, was a Phase I safety run-in, open-label dose escalation phase to characterize the safety and tolerability of Allocetra injections to the target knee in order to identify the dose and injection regimen for the subsequent Phase II stage.The Company previously announced that no serious adverse reactions were reported during or following treatment in the Phase I stage. The information below details the interim efficacy data with respect to the treatment of these patients, measured three months following the administration of Allocetra injections. The interim effic","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FIOoTYlhU1922yeFquiUhQ--~B/aD00Mjt3PTE1MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/500cdd9202d9cca9833167f70a85d1ba","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FIOoTYlhU1922yeFquiUhQ--~B/aD00Mjt3PTE1MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/500cdd9202d9cca9833167f70a85d1ba"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enlivex-announces-positive-interim-efficacy-154900817.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ENLV"],"gpt_icon":0},{"id":"2489199651","title":"Trump's crypto advocacy steers businesses away from traditional treasury assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2489199651","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489199651?lang=en_us&edition=fundamental","pubTime":"2024-12-05 00:32","pubTimestamp":1733329934,"startTime":"0","endTime":"0","summary":"Trump's crypto advocacy steers businesses away from traditional treasury assetsTrump's return to White House spurs bitcoin investmentBiotech firms set up to $1 mln treasury reserve targetSkeptics call out bitcoin's volatile natureBy Niket  Nishant and Bhanvi Satija. MicroStrategy MSTR.O, the largest corporate holder of bitcoin, pioneered the approach of integrating","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nL3N3N015K:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTM","MSTR","HOTH","BK4539","ENLV","BK4595","BK4563","BK4023","BK4137","BK4516","BK4585","BK4588","BK4596","ACXP","BK4007","BK4600","BK4139"],"gpt_icon":1},{"id":"2488948687","title":"Enlivex Reports Positive Results in Osteoarthritis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2488948687","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488948687?lang=en_us&edition=fundamental","pubTime":"2024-12-03 21:57","pubTimestamp":1733234262,"startTime":"0","endTime":"0","summary":"Enlivex (ENLV) has released an update. Enlivex Therapeutics has reported promising interim results from its Allocetra trial for knee osteoarthritis...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/enlivex-reports-positive-results-in-osteoarthritis-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/enlivex-reports-positive-results-in-osteoarthritis-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ENLV"],"gpt_icon":0},{"id":"2488910853","title":"Enlivex announces interim efficacy data from Phase I Allocetra trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2488910853","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488910853?lang=en_us&edition=fundamental","pubTime":"2024-12-03 21:35","pubTimestamp":1733232925,"startTime":"0","endTime":"0","summary":"Enlivex Therapeutics (ENLV) announced positive interim efficacy data from the Phase I stage of its randomized, multi-country Phase I/II Allocetra t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/enlivex-announces-interim-efficacy-data-from-phase-i-allocetra-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/enlivex-announces-interim-efficacy-data-from-phase-i-allocetra-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ENLV"],"gpt_icon":0},{"id":"2487910518","title":"Enlivex Therapeutics Faces Financial Challenges Amid Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2487910518","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487910518?lang=en_us&edition=fundamental","pubTime":"2024-11-30 05:58","pubTimestamp":1732917537,"startTime":"0","endTime":"0","summary":"Enlivex (ENLV) has released an update. Enlivex Therapeutics Ltd. reported a significant net loss of $9.8 million for the nine months ending Septemb...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/enlivex-therapeutics-faces-financial-challenges-amid-losses?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/enlivex-therapeutics-faces-financial-challenges-amid-losses?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","ENLV"],"gpt_icon":0},{"id":"2486007383","title":"Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3","url":"https://stock-news.laohu8.com/highlight/detail?id=2486007383","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486007383?lang=en_us&edition=fundamental","pubTime":"2024-11-26 23:15","pubTimestamp":1732634100,"startTime":"0","endTime":"0","summary":"NESS ZIONA, ISRAEL / ACCESSWIRE / November 26, 2024 / Enlivex Therapeutics Ltd. , a clinical-stage macrophage reprogramming immunotherapy company, is pleased to invite investors to a webinar on December 3, 2024, at 11:00 a.m. ET.The exclusive event, hosted by RedChip Companies, will feature Enlivex Therapeutics Chief Executive Officer Oren Hershkovitz who will share insight into the Company's lead product, Allocetra, insight into the clinical status, and 2025 planned catalysts.Allocetra is an off-the-shelf, cell therapy technology that reprograms non-homeostatic macrophages to their optimal functioning state, addressing critical unmet needs in conditions like osteoarthritis, sepsis, and psoriatic arthritis. With Phase I/II clinical trials showing promising results and targeting multi-billion-dollar markets, Allocetra has the potential to redefine treatment paradigms for inflammatory and autoimmune diseases.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/StCuUlZ6kiI77aswZvUxig--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/8bb34287933874f442490c8cb760fd05","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/StCuUlZ6kiI77aswZvUxig--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/8bb34287933874f442490c8cb760fd05"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/join-enlivex-therapeutics-exclusive-live-151500357.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","ENLV","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":27,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ENLV\",params:#limit:5,,,undefined,":[{"date":"2023-09-11","symbol":"ENLV","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1694419200000,"name":null,"time":"Pre-Market","dateTimestamp":1694404800000,"actualEps":null},{"market":"US","date":"2023-06-26","symbol":"ENLV","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1687752000000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2023-04-04","symbol":"ENLV","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1680580800000,"reportTimeType":"pre","actualEps":null},{"date":"2022-12-19","symbol":"ENLV","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1671440400000,"name":null,"time":"","dateTimestamp":1671426000000,"actualEps":null},{"market":"US","date":"2021-08-09","symbol":"ENLV","fiscalQuarterEnding":"2021/06","expectedEps":-0.26,"name":null,"time":"","type":"earning","dateTimestamp":1628481600000,"reportTimeType":"","actualEps":-0.17}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ENLV\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ENLV\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1724817600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ENLV\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ENLV","date":"2025-04-25","current":-1.512252,"percent":0.734959,"low":-42.250582,"twenty":-11.33139,"median":-3.219049,"eighty":-1.391372,"high":-0.807503,"avg":-6.644387,"sd":7.026249,"marketCap":22704949},"quantilePoints":[{"date":"2020-05-01","current":-7.391485,"twenty":-35.506879,"median":-12.885216,"eighty":-10.048413,"marketCap":69361693},{"date":"2020-05-08","current":-7.498089,"twenty":-35.367811,"median":-12.6477,"eighty":-10.007597,"marketCap":70362070},{"date":"2020-05-15","current":-7.126047,"twenty":-35.069452,"median":-12.618011,"eighty":-9.865149,"marketCap":66870822},{"date":"2020-05-22","current":-9.45474,"twenty":-34.905519,"median":-12.563258,"eighty":-9.768339,"marketCap":71033464},{"date":"2020-05-29","current":-9.276012,"twenty":-34.783914,"median":-12.516551,"eighty":-9.631581,"marketCap":69690676},{"date":"2020-06-05","current":-9.508359,"twenty":-34.389276,"median":-12.297891,"eighty":-9.552984,"marketCap":71436300},{"date":"2020-06-12","current":-9.722833,"twenty":-33.990313,"median":-12.127931,"eighty":-9.536411,"marketCap":73047645},{"date":"2020-06-19","current":-10.527112,"twenty":-33.735282,"median":-11.988581,"eighty":-9.552984,"marketCap":79090189},{"date":"2020-06-26","current":-11.027551,"twenty":-33.504338,"median":-11.768121,"eighty":-9.576846,"marketCap":82849994},{"date":"2020-07-02","current":-9.45474,"twenty":-33.462966,"median":-11.639761,"eighty":-9.533096,"marketCap":71033464},{"date":"2020-07-10","current":-9.229126,"twenty":-33.427523,"median":-11.600956,"eighty":-9.509858,"marketCap":69338420},{"date":"2020-07-17","current":-10.358125,"twenty":-33.350884,"median":-11.507353,"eighty":-9.50002,"marketCap":77820596},{"date":"2020-07-24","current":-9.874268,"twenty":-33.179332,"median":-11.474968,"eighty":-9.508359,"marketCap":74185378},{"date":"2020-07-31","current":-9.784665,"twenty":-32.588683,"median":-11.438542,"eighty":-9.509858,"marketCap":73512189},{"date":"2020-08-07","current":-9.408332,"twenty":-32.507148,"median":-11.42838,"eighty":-9.509858,"marketCap":70684797},{"date":"2020-08-14","current":-7.877187,"twenty":-32.203308,"median":-11.306688,"eighty":-9.50002,"marketCap":71627261},{"date":"2020-08-21","current":-7.270111,"twenty":-32.103906,"median":-11.237452,"eighty":-9.473006,"marketCap":66107115},{"date":"2020-08-28","current":-7.921607,"twenty":-31.963839,"median":-11.190585,"eighty":-9.45474,"marketCap":72031174},{"date":"2020-09-04","current":-7.358951,"twenty":-31.93161,"median":-11.135142,"eighty":-9.364312,"marketCap":66914941},{"date":"2020-09-11","current":-7.373758,"twenty":-31.809517,"median":-11.116916,"eighty":-9.32963,"marketCap":67049579},{"date":"2020-09-18","current":-7.81796,"twenty":-31.762012,"median":-11.079649,"eighty":-9.281178,"marketCap":71088710},{"date":"2020-09-25","current":-7.329338,"twenty":-31.447537,"median":-11.071367,"eighty":-9.139522,"marketCap":66645666},{"date":"2020-10-02","current":-15.324978,"twenty":-31.277823,"median":-11.064989,"eighty":-9.043665,"marketCap":139350029},{"date":"2020-10-09","current":-17.442343,"twenty":-30.847326,"median":-11.078127,"eighty":-9.07941,"marketCap":158603222},{"date":"2020-10-16","current":-19.530093,"twenty":-30.60981,"median":-11.102961,"eighty":-9.139522,"marketCap":177587139},{"date":"2020-10-23","current":-20.973581,"twenty":-30.605914,"median":-11.135142,"eighty":-9.214884,"marketCap":190712775},{"date":"2020-10-30","current":-18.001963,"twenty":-30.589877,"median":-11.190585,"eighty":-9.229126,"marketCap":158903323},{"date":"2020-11-06","current":-18.752044,"twenty":-30.554331,"median":-11.237452,"eighty":-9.276012,"marketCap":165524295},{"date":"2020-11-13","current":-15.132084,"twenty":-30.246813,"median":-11.306688,"eighty":-9.281178,"marketCap":133570909},{"date":"2020-11-20","current":-13.925431,"twenty":-30.090084,"median":-11.42838,"eighty":-9.293885,"marketCap":122919781},{"date":"2020-11-27","current":-14.05588,"twenty":-29.543927,"median":-11.438457,"eighty":-9.296979,"marketCap":124071254},{"date":"2020-12-04","current":-18.458534,"twenty":-29.293282,"median":-11.464493,"eighty":-9.300197,"marketCap":162933480},{"date":"2020-12-11","current":-16.550717,"twenty":-28.726626,"median":-11.479528,"eighty":-9.323866,"marketCap":146093182},{"date":"2020-12-18","current":-17.757371,"twenty":-28.589355,"median":-11.575956,"eighty":-9.343904,"marketCap":156744311},{"date":"2020-12-24","current":-17.023595,"twenty":-28.468598,"median":-11.624687,"eighty":-9.347491,"marketCap":150267273},{"date":"2020-12-31","current":-13.746064,"twenty":-28.173958,"median":-11.643303,"eighty":-9.35412,"marketCap":121336505},{"date":"2021-01-08","current":-15.931538,"twenty":-27.574936,"median":-11.920309,"eighty":-9.364578,"marketCap":140627683},{"date":"2021-01-15","current":-17.336289,"twenty":-27.118197,"median":-12.046285,"eighty":-9.382558,"marketCap":153027427},{"date":"2021-01-22","current":-19.914422,"twenty":-27.024496,"median":-12.223595,"eighty":-9.409419,"marketCap":175784604},{"date":"2021-01-29","current":-19.749157,"twenty":-26.84195,"median":-12.469564,"eighty":-9.421961,"marketCap":174325811},{"date":"2021-02-05","current":-31.400334,"twenty":-26.84195,"median":-12.529307,"eighty":-9.45474,"marketCap":277170746},{"date":"2021-02-12","current":-38.255446,"twenty":-28.281254,"median":-12.60197,"eighty":-9.456211,"marketCap":337680820},{"date":"2021-02-19","current":-37.135481,"twenty":-29.264756,"median":-12.640235,"eighty":-9.462094,"marketCap":327794891},{"date":"2021-02-26","current":-31.703043,"twenty":-30.554331,"median":-12.659911,"eighty":-9.472613,"marketCap":279842763},{"date":"2021-03-05","current":-26.934109,"twenty":-30.554331,"median":-12.982325,"eighty":-9.472613,"marketCap":237747383},{"date":"2021-03-12","current":-29.73593,"twenty":-30.417505,"median":-13.33841,"eighty":-9.474579,"marketCap":262479052},{"date":"2021-03-19","current":-27.939384,"twenty":-30.246813,"median":-13.55039,"eighty":-9.480014,"marketCap":246620943},{"date":"2021-03-26","current":-22.776896,"twenty":-30.090084,"median":-13.669721,"eighty":-9.490486,"marketCap":201051663},{"date":"2021-04-01","current":-23.313795,"twenty":-29.806761,"median":-13.754217,"eighty":-9.496445,"marketCap":205790868},{"date":"2021-04-09","current":-24.201743,"twenty":-29.62029,"median":-13.925431,"eighty":-9.506274,"marketCap":213628784},{"date":"2021-04-16","current":-22.652996,"twenty":-29.444186,"median":-14.142214,"eighty":-9.508359,"marketCap":199958000},{"date":"2021-04-23","current":-21.22815,"twenty":-29.293282,"median":-14.496146,"eighty":-9.514357,"marketCap":187380879},{"date":"2021-04-30","current":-17.711306,"twenty":-29.261736,"median":-15.17285,"eighty":-9.526996,"marketCap":209418477},{"date":"2021-05-07","current":-15.543838,"twenty":-28.831462,"median":-15.324978,"eighty":-9.541239,"marketCap":183790342},{"date":"2021-05-14","current":-14.537514,"twenty":-28.618492,"median":-15.17285,"eighty":-9.545905,"marketCap":171891565},{"date":"2021-05-21","current":-15.404501,"twenty":-28.589355,"median":-15.213615,"eighty":-9.550629,"marketCap":182142819},{"date":"2021-05-28","current":-12.053791,"twenty":-28.428574,"median":-15.07164,"eighty":-9.551697,"marketCap":171525449},{"date":"2021-06-04","current":-12.529768,"twenty":-28.19339,"median":-15.033591,"eighty":-9.558436,"marketCap":178298599},{"date":"2021-06-11","current":-12.285348,"twenty":-27.988944,"median":-14.630405,"eighty":-9.583805,"marketCap":174820495},{"date":"2021-06-18","current":-12.040927,"twenty":-27.886995,"median":-14.552996,"eighty":-9.608447,"marketCap":171342390},{"date":"2021-06-25","current":-11.938013,"twenty":-27.607099,"median":-14.369688,"eighty":-9.620266,"marketCap":169877926},{"date":"2021-07-02","current":-11.449172,"twenty":-27.273056,"median":-14.210669,"eighty":-9.642686,"marketCap":162921717},{"date":"2021-07-09","current":-10.522947,"twenty":-27.118197,"median":-14.096646,"eighty":-9.664912,"marketCap":149741533},{"date":"2021-07-16","current":-9.596722,"twenty":-27.015919,"median":-13.794982,"eighty":-9.664912,"marketCap":136561350},{"date":"2021-07-23","current":-9.570993,"twenty":-26.94655,"median":-13.721605,"eighty":-9.636251,"marketCap":136195233},{"date":"2021-07-30","current":-9.776821,"twenty":-26.925815,"median":-13.631921,"eighty":-9.628153,"marketCap":139124163},{"date":"2021-08-06","current":-10.589086,"twenty":-26.906399,"median":-13.428095,"eighty":-9.643412,"marketCap":151392158},{"date":"2021-08-13","current":-13.021886,"twenty":-26.825976,"median":-13.329925,"eighty":-9.664912,"marketCap":186173911},{"date":"2021-08-20","current":-13.226754,"twenty":-26.712777,"median":-13.317861,"eighty":-9.682201,"marketCap":189102901},{"date":"2021-08-27","current":-15.326645,"twenty":-26.670636,"median":-13.371023,"eighty":-9.692107,"marketCap":219125046},{"date":"2021-09-03","current":-15.00654,"twenty":-26.583373,"median":-13.517778,"eighty":-9.704975,"marketCap":214548499},{"date":"2021-09-10","current":-14.507175,"twenty":-26.507376,"median":-13.595792,"eighty":-9.714953,"marketCap":207409087},{"date":"2021-09-17","current":-14.91691,"twenty":-26.456266,"median":-13.697145,"eighty":-9.724684,"marketCap":213267066},{"date":"2021-09-24","current":-14.238287,"twenty":-26.422703,"median":-13.754217,"eighty":-9.741035,"marketCap":203564788},{"date":"2021-10-01","current":-12.154068,"twenty":-26.305176,"median":-13.713314,"eighty":-9.77839,"marketCap":173766711},{"date":"2021-10-08","current":-12.166875,"twenty":-26.15391,"median":-13.637109,"eighty":-9.784665,"marketCap":173949816},{"date":"2021-10-15","current":-11.885116,"twenty":-25.995727,"median":-13.55039,"eighty":-9.786233,"marketCap":169921504},{"date":"2021-10-22","current":-10.822115,"twenty":-25.825302,"median":-13.476436,"eighty":-9.79287,"marketCap":154723784},{"date":"2021-10-29","current":-10.553163,"twenty":-25.732176,"median":-13.329925,"eighty":-9.797932,"marketCap":150878577},{"date":"2021-11-05","current":-11.167911,"twenty":-25.699442,"median":-13.233156,"eighty":-9.814162,"marketCap":159667621},{"date":"2021-11-12","current":-10.578778,"twenty":-25.692352,"median":-13.021886,"eighty":-9.824129,"marketCap":151244787},{"date":"2021-11-19","current":-9.367411,"twenty":-25.673789,"median":-12.93377,"eighty":-9.824129,"marketCap":146094140},{"date":"2021-11-26","current":-8.897277,"twenty":-25.599535,"median":-12.742452,"eighty":-9.792506,"marketCap":138761937},{"date":"2021-12-03","current":-7.63967,"twenty":-25.590971,"median":-12.6477,"eighty":-9.732088,"marketCap":119148295},{"date":"2021-12-10","current":-7.81597,"twenty":-25.590971,"median":-12.629123,"eighty":-9.687087,"marketCap":121897871},{"date":"2021-12-17","current":-7.369343,"twenty":-25.558271,"median":-12.60197,"eighty":-9.623379,"marketCap":114932278},{"date":"2021-12-23","current":-7.28707,"twenty":-25.472761,"median":-12.542632,"eighty":-9.591576,"marketCap":113649143},{"date":"2021-12-31","current":-7.345837,"twenty":-25.399668,"median":-12.526145,"eighty":-9.556843,"marketCap":114565668},{"date":"2022-01-07","current":-7.099017,"twenty":-25.345397,"median":-12.520418,"eighty":-9.541239,"marketCap":110716262},{"date":"2022-01-14","current":-6.89921,"twenty":-25.261359,"median":-12.494045,"eighty":-9.506274,"marketCap":107600076},{"date":"2022-01-21","current":-6.464336,"twenty":-25.089038,"median":-12.473937,"eighty":-9.47784,"marketCap":100817788},{"date":"2022-01-28","current":-6.052969,"twenty":-24.79081,"median":-12.388261,"eighty":-9.459152,"marketCap":94402111},{"date":"2022-02-04","current":-5.817903,"twenty":-24.524483,"median":-12.339773,"eighty":-9.391964,"marketCap":90736009},{"date":"2022-02-11","current":-6.005956,"twenty":-24.41624,"median":-12.285348,"eighty":-9.347491,"marketCap":93668890},{"date":"2022-02-18","current":-6.147331,"twenty":-24.282838,"median":-12.223595,"eighty":-9.296205,"marketCap":95873781},{"date":"2022-02-25","current":-6.029792,"twenty":-24.185223,"median":-12.179682,"eighty":-9.24788,"marketCap":94040630},{"date":"2022-03-04","current":-5.81822,"twenty":-24.147801,"median":-12.154068,"eighty":-9.057963,"marketCap":90740959},{"date":"2022-03-11","current":-6.241363,"twenty":-23.991611,"median":-12.073087,"eighty":-8.920086,"marketCap":97340302},{"date":"2022-03-18","current":-6.300133,"twenty":-23.753921,"median":-12.040927,"eighty":-8.750736,"marketCap":98256877},{"date":"2022-03-25","current":-6.382411,"twenty":-23.656584,"median":-11.969729,"eighty":-8.684531,"marketCap":99540083},{"date":"2022-04-01","current":-6.717399,"twenty":-23.573984,"median":-11.938013,"eighty":-8.511768,"marketCap":104764562},{"date":"2022-04-08","current":-9.544232,"twenty":-23.553334,"median":-11.922729,"eighty":-8.511768,"marketCap":148851836},{"date":"2022-04-14","current":-8.686191,"twenty":-23.540944,"median":-11.894412,"eighty":-8.34487,"marketCap":135469836},{"date":"2022-04-22","current":-7.851659,"twenty":-23.495514,"median":-11.860828,"eighty":-8.255074,"marketCap":122454466},{"date":"2022-04-29","current":-7.225933,"twenty":-23.289015,"median":-11.77721,"eighty":-8.169363,"marketCap":104544799},{"date":"2022-05-06","current":-5.435324,"twenty":-23.166112,"median":-11.645343,"eighty":-8.041478,"marketCap":78638267},{"date":"2022-05-13","current":-5.435324,"twenty":-23.069985,"median":-11.624687,"eighty":-7.969071,"marketCap":78638267},{"date":"2022-05-20","current":-5.11784,"twenty":-23.032956,"median":-11.577814,"eighty":-7.881398,"marketCap":74044910},{"date":"2022-05-27","current":-4.448909,"twenty":-22.876016,"median":-11.551542,"eighty":-7.852492,"marketCap":86722575},{"date":"2022-06-03","current":-4.863637,"twenty":-22.776896,"median":-11.537249,"eighty":-7.827724,"marketCap":94806883},{"date":"2022-06-10","current":-4.010616,"twenty":-22.652996,"median":-11.500899,"eighty":-7.81597,"marketCap":78178931},{"date":"2022-06-17","current":-3.760836,"twenty":-22.529097,"median":-11.477248,"eighty":-7.72912,"marketCap":73309973},{"date":"2022-06-24","current":-4.373503,"twenty":-22.446497,"median":-11.464459,"eighty":-7.681738,"marketCap":85252701},{"date":"2022-07-01","current":-4.203842,"twenty":-22.376287,"median":-11.449172,"eighty":-7.640252,"marketCap":81945484},{"date":"2022-07-08","current":-5.278366,"twenty":-22.305556,"median":-11.438627,"eighty":-7.613627,"marketCap":102891191},{"date":"2022-07-15","current":-4.627996,"twenty":-22.101984,"median":-11.428444,"eighty":-7.55138,"marketCap":90213526},{"date":"2022-07-22","current":-3.987052,"twenty":-21.967418,"median":-11.387691,"eighty":-7.503446,"marketCap":77719596},{"date":"2022-07-29","current":-4.005903,"twenty":-21.913728,"median":-11.301792,"eighty":-7.431035,"marketCap":78087064},{"date":"2022-08-05","current":-4.863637,"twenty":-21.888948,"median":-11.237452,"eighty":-7.399356,"marketCap":94806883},{"date":"2022-08-12","current":-4.797658,"twenty":-21.862089,"median":-11.216095,"eighty":-7.353705,"marketCap":93520743},{"date":"2022-08-19","current":-4.825935,"twenty":-21.677916,"median":-11.173407,"eighty":-7.324758,"marketCap":94071946},{"date":"2022-08-26","current":-4.004998,"twenty":-21.508695,"median":-11.14152,"eighty":-7.292354,"marketCap":105323427},{"date":"2022-09-02","current":-3.606595,"twenty":-21.463334,"median":-11.116916,"eighty":-7.270111,"marketCap":94846228},{"date":"2022-09-09","current":-3.424867,"twenty":-21.405349,"median":-11.08117,"eighty":-7.237681,"marketCap":90067154},{"date":"2022-09-16","current":-3.368951,"twenty":-21.286149,"median":-11.075135,"eighty":-7.177095,"marketCap":88596670},{"date":"2022-09-23","current":-2.872695,"twenty":-21.208634,"median":-11.058612,"eighty":-7.086181,"marketCap":75546123},{"date":"2022-09-30","current":-2.970548,"twenty":-21.177073,"median":-11.028796,"eighty":-7.033351,"marketCap":78119471},{"date":"2022-10-07","current":-2.98112,"twenty":-21.121105,"median":-11.001417,"eighty":-6.964376,"marketCap":78397482},{"date":"2022-10-14","current":-2.918138,"twenty":-21.020838,"median":-10.97259,"eighty":-6.897942,"marketCap":76741198},{"date":"2022-10-21","current":-3.042212,"twenty":-20.985326,"median":-10.924573,"eighty":-6.845568,"marketCap":80004079},{"date":"2022-10-28","current":-3.019608,"twenty":-20.977642,"median":-10.867286,"eighty":-6.810107,"marketCap":79409656},{"date":"2022-11-04","current":-3.009111,"twenty":-20.903933,"median":-10.84773,"eighty":-6.664507,"marketCap":79133609},{"date":"2022-11-11","current":-3.219049,"twenty":-20.756177,"median":-10.82938,"eighty":-6.546173,"marketCap":84654559},{"date":"2022-11-18","current":-3.358938,"twenty":-20.668581,"median":-10.726981,"eighty":-6.478794,"marketCap":88333351},{"date":"2022-11-25","current":-3.261037,"twenty":-20.630862,"median":-10.714226,"eighty":-6.373008,"marketCap":85758748},{"date":"2022-12-02","current":-2.870497,"twenty":-20.600195,"median":-10.688457,"eighty":-6.299858,"marketCap":82116306},{"date":"2022-12-09","current":-2.773956,"twenty":-20.530642,"median":-10.652221,"eighty":-6.276625,"marketCap":79354547},{"date":"2022-12-16","current":-2.568001,"twenty":-20.466533,"median":-10.603143,"eighty":-6.251552,"marketCap":73462794},{"date":"2022-12-23","current":-2.50364,"twenty":-20.27992,"median":-10.586676,"eighty":-6.168488,"marketCap":71621621},{"date":"2022-12-30","current":-2.534211,"twenty":-20.15537,"median":-10.584284,"eighty":-6.147331,"marketCap":72496179},{"date":"2023-01-06","current":-2.735339,"twenty":-20.094824,"median":-10.578778,"eighty":-6.048334,"marketCap":78249844},{"date":"2023-01-13","current":-2.812057,"twenty":-20.035005,"median":-10.550787,"eighty":-6.001255,"marketCap":80444521},{"date":"2023-01-20","current":-2.670978,"twenty":-19.978946,"median":-10.539281,"eighty":-5.966125,"marketCap":76408671},{"date":"2023-01-27","current":-2.844753,"twenty":-19.92865,"median":-10.527112,"eighty":-5.924006,"marketCap":81379837},{"date":"2023-02-03","current":-2.83188,"twenty":-19.914681,"median":-10.518845,"eighty":-5.829586,"marketCap":81011603},{"date":"2023-02-10","current":-2.7997,"twenty":-19.912392,"median":-10.5062,"eighty":-5.803799,"marketCap":80091016},{"date":"2023-02-17","current":-2.638798,"twenty":-19.895957,"median":-10.459125,"eighty":-5.435324,"marketCap":75488084},{"date":"2023-02-24","current":-2.471459,"twenty":-19.873903,"median":-10.442134,"eighty":-5.343888,"marketCap":70701035},{"date":"2023-03-03","current":-2.53582,"twenty":-19.846258,"median":-10.408105,"eighty":-5.257533,"marketCap":72542208},{"date":"2023-03-10","current":-2.336301,"twenty":-19.83179,"median":-10.356918,"eighty":-5.11784,"marketCap":66834572},{"date":"2023-03-17","current":-2.291249,"twenty":-19.827342,"median":-10.280555,"eighty":-4.987615,"marketCap":65545751},{"date":"2023-03-24","current":-2.297685,"twenty":-19.792064,"median":-10.24585,"eighty":-4.882489,"marketCap":65729868},{"date":"2023-03-31","current":-2.342737,"twenty":-19.702524,"median":-10.187527,"eighty":-4.844757,"marketCap":67018689},{"date":"2023-04-06","current":-1.686256,"twenty":-19.632558,"median":-10.178515,"eighty":-4.82782,"marketCap":48238727},{"date":"2023-04-14","current":-1.761523,"twenty":-19.623856,"median":-10.152662,"eighty":-4.778806,"marketCap":54712900},{"date":"2023-04-21","current":-1.74373,"twenty":-19.588234,"median":-10.098427,"eighty":-4.644962,"marketCap":54160244},{"date":"2023-04-28","current":-1.714074,"twenty":-19.576906,"median":-10.035554,"eighty":-4.518659,"marketCap":53239152},{"date":"2023-05-05","current":-1.654764,"twenty":-19.545187,"median":-10.025454,"eighty":-4.450794,"marketCap":51396967},{"date":"2023-05-12","current":-1.672557,"twenty":-19.516872,"median":-10.012699,"eighty":-4.39047,"marketCap":51949622},{"date":"2023-05-19","current":-1.589522,"twenty":-19.460547,"median":-9.999892,"eighty":-4.266051,"marketCap":49370563},{"date":"2023-05-26","current":-1.57766,"twenty":-19.427915,"median":-9.975789,"eighty":-4.215152,"marketCap":49002126},{"date":"2023-06-02","current":-1.506488,"twenty":-19.352412,"median":-9.936043,"eighty":-4.127494,"marketCap":46791504},{"date":"2023-06-09","current":-1.601384,"twenty":-19.277733,"median":-9.905463,"eighty":-4.005903,"marketCap":49739000},{"date":"2023-06-16","current":-1.666626,"twenty":-19.224922,"median":-9.888874,"eighty":-3.984029,"marketCap":51765404},{"date":"2023-06-22","current":-1.685692,"twenty":-19.216442,"median":-9.879735,"eighty":-3.907876,"marketCap":50660093},{"date":"2023-06-30","current":-1.590794,"twenty":-19.208775,"median":-9.865308,"eighty":-3.854893,"marketCap":47808124},{"date":"2023-07-07","current":-1.507393,"twenty":-19.20072,"median":-9.828261,"eighty":-3.760836,"marketCap":45301679},{"date":"2023-07-14","current":-1.427081,"twenty":-19.193508,"median":-9.794325,"eighty":-3.690469,"marketCap":42888065},{"date":"2023-07-21","current":-1.507393,"twenty":-19.088098,"median":-9.784665,"eighty":-3.638302,"marketCap":45301679},{"date":"2023-07-28","current":-1.47082,"twenty":-18.913767,"median":-9.732088,"eighty":-3.592616,"marketCap":44202556},{"date":"2023-08-04","current":-1.834818,"twenty":-18.866187,"median":-9.706309,"eighty":-3.410888,"marketCap":55141798},{"date":"2023-08-11","current":-1.587705,"twenty":-18.752044,"median":-9.678943,"eighty":-3.358938,"marketCap":47715293},{"date":"2023-08-18","current":-1.54446,"twenty":-18.637901,"median":-9.629347,"eighty":-3.268035,"marketCap":46415655},{"date":"2023-08-25","current":-1.482682,"twenty":-18.599214,"median":-9.603002,"eighty":-3.22916,"marketCap":44559028},{"date":"2023-09-01","current":-1.476504,"twenty":-18.588983,"median":-9.583858,"eighty":-3.170064,"marketCap":44373366},{"date":"2023-09-08","current":-1.599351,"twenty":-18.484624,"median":-9.566961,"eighty":-3.120328,"marketCap":43073727},{"date":"2023-09-15","current":-1.305186,"twenty":-18.093277,"median":-9.551697,"eighty":-3.053757,"marketCap":35151268},{"date":"2023-09-22","current":-1.084202,"twenty":-17.998272,"median":-9.545293,"eighty":-3.017509,"marketCap":29199731},{"date":"2023-09-29","current":-1.035862,"twenty":-17.946983,"median":-9.529781,"eighty":-3.000867,"marketCap":27897832},{"date":"2023-10-06","current":-1.069424,"twenty":-17.910179,"median":-9.508359,"eighty":-2.980403,"marketCap":28801722},{"date":"2023-10-13","current":-0.92537,"twenty":-17.786722,"median":-9.490486,"eighty":-2.958726,"marketCap":24922063},{"date":"2023-10-20","current":-0.994427,"twenty":-17.748788,"median":-9.473596,"eighty":-2.934164,"marketCap":26781919},{"date":"2023-10-27","current":-0.904653,"twenty":-17.745767,"median":-9.472613,"eighty":-2.925793,"marketCap":24364107},{"date":"2023-11-03","current":-0.97371,"twenty":-17.742028,"median":-9.45474,"eighty":-2.910919,"marketCap":26223962},{"date":"2023-11-10","current":-1.208506,"twenty":-17.735112,"median":-9.411049,"eighty":-2.890849,"marketCap":32547471},{"date":"2023-11-17","current":-1.191425,"twenty":-17.657513,"median":-9.365376,"eighty":-2.873386,"marketCap":32361485},{"date":"2023-11-24","current":-1.321523,"twenty":-17.442343,"median":-9.347503,"eighty":-2.851189,"marketCap":35895211},{"date":"2023-12-01","current":-1.259898,"twenty":-17.38233,"median":-9.315219,"eighty":-2.83188,"marketCap":34221341},{"date":"2023-12-08","current":-1.170883,"twenty":-17.336289,"median":-9.293885,"eighty":-2.806136,"marketCap":31803529},{"date":"2023-12-15","current":-0.986007,"twenty":-17.300799,"median":-9.252569,"eighty":-2.773956,"marketCap":26781919},{"date":"2023-12-22","current":-1.561178,"twenty":-17.246848,"median":-9.139522,"eighty":-2.767519,"marketCap":42404705},{"date":"2023-12-29","current":-1.766596,"twenty":-17.221185,"median":-9.061538,"eighty":-2.760774,"marketCap":47984271},{"date":"2024-01-05","current":-2.506101,"twenty":-17.167981,"median":-8.982854,"eighty":-2.752073,"marketCap":68070711},{"date":"2024-01-12","current":-2.067876,"twenty":-17.020028,"median":-8.925788,"eighty":-2.723754,"marketCap":56167636},{"date":"2024-01-19","current":-1.828221,"twenty":-17.00576,"median":-8.789589,"eighty":-2.677414,"marketCap":49658141},{"date":"2024-01-26","current":-1.985708,"twenty":-16.968174,"median":-8.734252,"eighty":-2.645234,"marketCap":53935809},{"date":"2024-02-02","current":-1.882999,"twenty":-16.939654,"median":-8.685954,"eighty":-2.625925,"marketCap":51146026},{"date":"2024-02-09","current":-1.807679,"twenty":-16.938913,"median":-8.684531,"eighty":-2.593745,"marketCap":49100185},{"date":"2024-02-16","current":-2.197974,"twenty":-16.925758,"median":-8.618237,"eighty":-2.567726,"marketCap":59701361},{"date":"2024-02-23","current":-2.115806,"twenty":-16.770447,"median":-8.515294,"eighty":-2.531958,"marketCap":57469534},{"date":"2024-03-01","current":-2.126077,"twenty":-16.704302,"median":-8.333117,"eighty":-2.50364,"marketCap":57748513},{"date":"2024-03-08","current":-2.314377,"twenty":-16.616611,"median":-8.290129,"eighty":-2.482023,"marketCap":62863115},{"date":"2024-03-15","current":-2.821075,"twenty":-16.559853,"median":-8.227337,"eighty":-2.484293,"marketCap":76626046},{"date":"2024-03-22","current":-2.45817,"twenty":-16.504894,"median":-8.169883,"eighty":-2.484293,"marketCap":66768812},{"date":"2024-03-28","current":-2.643046,"twenty":-16.389693,"median":-8.076394,"eighty":-2.485232,"marketCap":71790422},{"date":"2024-04-05","current":-2.405758,"twenty":-15.948064,"median":-7.968764,"eighty":-2.478712,"marketCap":69930566},{"date":"2024-04-12","current":-1.170887,"twenty":-15.749184,"median":-7.872428,"eighty":-2.477895,"marketCap":34035355},{"date":"2024-04-19","current":-0.895761,"twenty":-15.429079,"median":-7.832767,"eighty":-2.455369,"marketCap":26037977},{"date":"2024-04-26","current":-0.938389,"twenty":-15.339387,"median":-7.81597,"eighty":-2.391538,"marketCap":27277081},{"date":"2024-05-03","current":-1.048407,"twenty":-15.197309,"median":-7.721716,"eighty":-2.342737,"marketCap":30475083},{"date":"2024-05-10","current":-0.98369,"twenty":-15.027656,"median":-7.656232,"eighty":-2.318762,"marketCap":28593905},{"date":"2024-05-17","current":-0.90603,"twenty":-14.795359,"median":-7.610665,"eighty":-2.292536,"marketCap":26336492},{"date":"2024-05-24","current":-0.886421,"twenty":-14.604487,"median":-7.535422,"eighty":-2.26208,"marketCap":25766495},{"date":"2024-05-31","current":-0.948916,"twenty":-14.531446,"median":-7.494663,"eighty":-2.239057,"marketCap":27583083},{"date":"2024-06-07","current":-0.970075,"twenty":-14.326486,"median":-7.40862,"eighty":-2.197974,"marketCap":28198129},{"date":"2024-06-14","current":-1.039667,"twenty":-14.137411,"median":-7.369343,"eighty":-2.115806,"marketCap":30221038},{"date":"2024-06-21","current":-1.062541,"twenty":-14.007811,"median":-7.327858,"eighty":-2.065137,"marketCap":27615452},{"date":"2024-06-28","current":-1.204604,"twenty":-13.78846,"median":-7.297759,"eighty":-2.010359,"marketCap":31307670},{"date":"2024-07-05","current":-1.068083,"twenty":-13.686175,"median":-7.275317,"eighty":-1.965166,"marketCap":27759467},{"date":"2024-07-12","current":-1.140359,"twenty":-13.4847,"median":-7.225933,"eighty":-1.911758,"marketCap":29637927},{"date":"2024-07-15","current":-1.188543,"twenty":-13.480277,"median":-7.22569,"eighty":-1.899433,"marketCap":30890234},{"date":"2024-08-02","current":-1.068083,"twenty":-12.841755,"median":-7.076567,"eighty":-1.873413,"marketCap":27759467},{"date":"2024-08-09","current":-1.01323,"twenty":-12.643221,"median":-7.016084,"eighty":-1.812305,"marketCap":26333856},{"date":"2024-08-16","current":-0.994348,"twenty":-12.560908,"median":-6.91684,"eighty":-1.766596,"marketCap":25843098},{"date":"2024-08-23","current":-1.036532,"twenty":-12.52126,"median":-6.849695,"eighty":-1.758351,"marketCap":26939472},{"date":"2024-08-30","current":-1.000374,"twenty":-12.473063,"median":-6.799492,"eighty":-1.736271,"marketCap":25999723},{"date":"2024-09-06","current":-1.15217,"twenty":-12.364107,"median":-6.617311,"eighty":-1.714074,"marketCap":25686473},{"date":"2024-09-13","current":-1.48939,"twenty":-12.253473,"median":-6.523281,"eighty":-1.688712,"marketCap":33204466},{"date":"2024-09-20","current":-1.405085,"twenty":-12.158042,"median":-6.376534,"eighty":-1.682047,"marketCap":31324968},{"date":"2024-09-27","current":-1.480023,"twenty":-12.045958,"median":-6.294084,"eighty":-1.667461,"marketCap":32995632},{"date":"2024-10-04","current":-1.480023,"twenty":-11.943159,"median":-6.276454,"eighty":-1.655339,"marketCap":32995632},{"date":"2024-10-11","current":-1.430653,"twenty":-11.893709,"median":-6.211978,"eighty":-1.650019,"marketCap":31894986},{"date":"2024-10-18","current":-1.565077,"twenty":-11.8243,"median":-6.129701,"eighty":-1.628561,"marketCap":34891830},{"date":"2024-10-25","current":-1.459458,"twenty":-11.642894,"median":-6.018038,"eighty":-1.618203,"marketCap":32537167},{"date":"2024-10-31","current":-1.325035,"twenty":-11.642894,"median":-5.976572,"eighty":-1.608313,"marketCap":29540322},{"date":"2024-11-08","current":-1.219416,"twenty":-11.643711,"median":-5.888744,"eighty":-1.60059,"marketCap":27185659},{"date":"2024-11-15","current":-1.036984,"twenty":-11.643711,"median":-5.81822,"eighty":-1.590031,"marketCap":23118513},{"date":"2024-11-22","current":-0.807503,"twenty":-11.643711,"median":-5.486121,"eighty":-1.582353,"marketCap":18002472},{"date":"2024-11-29","current":-1.094594,"twenty":-11.643711,"median":-5.397226,"eighty":-1.572515,"marketCap":24402875},{"date":"2024-12-06","current":-1.416956,"twenty":-11.643711,"median":-5.257533,"eighty":-1.561904,"marketCap":26827233},{"date":"2024-12-13","current":-1.405342,"twenty":-11.643711,"median":-5.054343,"eighty":-1.546931,"marketCap":26607338},{"date":"2024-12-20","current":-1.370499,"twenty":-11.607051,"median":-4.90134,"eighty":-1.532584,"marketCap":25947652},{"date":"2024-12-27","current":-1.4518,"twenty":-11.552128,"median":-4.863637,"eighty":-1.513321,"marketCap":27486920},{"date":"2025-01-03","current":-1.440185,"twenty":-11.551659,"median":-4.83536,"eighty":-1.507393,"marketCap":27267024},{"date":"2025-01-10","current":-1.370499,"twenty":-11.551894,"median":-4.778806,"eighty":-1.501215,"marketCap":25947652},{"date":"2025-01-17","current":-1.335656,"twenty":-11.533445,"median":-4.609145,"eighty":-1.488965,"marketCap":25287966},{"date":"2025-01-24","current":-1.382113,"twenty":-11.478602,"median":-4.496037,"eighty":-1.480555,"marketCap":26167547},{"date":"2025-01-31","current":-1.289198,"twenty":-11.469754,"median":-4.439483,"eighty":-1.471957,"marketCap":24408384},{"date":"2025-02-07","current":-1.196283,"twenty":-11.469754,"median":-4.293385,"eighty":-1.469209,"marketCap":22649222},{"date":"2025-02-14","current":-1.207897,"twenty":-11.469754,"median":-4.21798,"eighty":-1.451921,"marketCap":22869117},{"date":"2025-02-21","current":-1.18281,"twenty":-11.449172,"median":-4.115172,"eighty":-1.4518,"marketCap":22394143},{"date":"2025-02-28","current":-1.196283,"twenty":-11.43059,"median":-4.000737,"eighty":-1.440659,"marketCap":22649222},{"date":"2025-03-07","current":-1.335656,"twenty":-11.33139,"median":-3.902221,"eighty":-1.428571,"marketCap":25287966},{"date":"2025-03-14","current":-1.265969,"twenty":-11.33139,"median":-3.760836,"eighty":-1.425853,"marketCap":23968594},{"date":"2025-03-21","current":-1.265969,"twenty":-11.33139,"median":-3.68348,"eighty":-1.414452,"marketCap":23968594},{"date":"2025-03-28","current":-1.173054,"twenty":-11.33139,"median":-3.613584,"eighty":-1.405085,"marketCap":22209431},{"date":"2025-04-04","current":-1.386099,"twenty":-11.33139,"median":-3.424867,"eighty":-1.393728,"marketCap":20810896},{"date":"2025-04-11","current":-1.449241,"twenty":-11.329432,"median":-3.358973,"eighty":-1.393728,"marketCap":21758909},{"date":"2025-04-17","current":-1.354726,"twenty":-11.329432,"median":-3.271534,"eighty":-1.393728,"marketCap":20339850},{"date":"2025-04-25","current":-1.512252,"twenty":-11.33139,"median":-3.219049,"eighty":-1.391372,"marketCap":22704949}],"updateTime":1745837097187}}}